US stock futures flat after Wall St drops on Trump tariffs, soft jobs data
Catriona Yale, Chief Development Officer of Akero Therapeutics (NASDAQ:AKRO), sold 9,900 shares of common stock on June 16, 2025, for approximately $542,306. The transaction comes as the stock trades near its 52-week high of $58.40, having delivered an impressive 152% return over the past year according to InvestingPro data. The sales occurred in multiple transactions with prices ranging from $53.78 to $55.519.
Yale also exercised options to acquire 10,000 shares of Akero Therapeutics common stock at a price of $21.1 per share, for a total value of $211,000.
Following these transactions, Yale directly owns 92,231 shares of Akero Therapeutics.
In other recent news, Akero Therapeutics has reported promising results from its Phase 2b SYMMETRY trial, indicating that its drug efruxifermin (EFX) may improve liver fibrosis in patients with compensated cirrhosis caused by metabolic dysfunction-associated steatohepatitis (MASH). The trial showed improvements in non-invasive markers of liver injury and fibrosis, with a favorable safety profile. Additionally, Akero’s financial position remains strong, with $1.1 billion in cash reserves expected to fund operations into 2028, according to Morgan Stanley (NYSE:MS). Meanwhile, Jefferies has maintained a Buy rating with a $75 price target, highlighting the robust placebo-controlled data for Akero’s FGF21 therapy. Citi also sustained a Buy rating but adjusted its price target to $78, noting the positive effects of efruxifermin treatment on liver fibrosis metrics. Morgan Stanley lowered its price target to $84, reflecting a more cautious timeline for EFX’s market entry but maintained an Overweight rating. Clear Street initiated coverage with a Buy rating and a $49 price target, praising EFX’s potential in treating non-alcoholic steatohepatitis (NASH). These developments underscore the ongoing interest and analysis from various financial firms regarding Akero’s clinical progress and market potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.